A
24.11
-0.69 (-2.78%)
| Penutupan Terdahulu | 24.80 |
| Buka | 23.89 |
| Jumlah Dagangan | 1,741,918 |
| Purata Dagangan (3B) | 1,508,354 |
| Modal Pasaran | 2,898,311,424 |
| Harga / Jualan (P/S) | 329.72 |
| Harga / Buku (P/B) | 2.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2025 - 12 May 2025 |
| Margin Operasi (TTM) | -4,069.63% |
| EPS Cair (TTM) | -2.89 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 35.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.48% |
| Nisbah Semasa (MRQ) | 15.73 |
| Aliran Tunai Operasi (OCF TTM) | -300.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -197.47 M |
| Pulangan Atas Aset (ROA TTM) | -21.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Avidity Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
1.9
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.02% |
| % Dimiliki oleh Institusi | 107.83% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 72.00 (HC Wainwright & Co., 198.63%) | Beli |
| 72.00 (BMO Capital, 198.63%) | Beli | |
| Median | 67.50 (179.97%) | |
| Rendah | 48.00 (B of A Securities, 99.09%) | Beli |
| Purata | 64.25 (166.49%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 30.40 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 09 May 2025 | 65.00 (169.60%) | Beli | 32.20 |
| 07 May 2025 | 65.00 (169.60%) | Beli | 32.20 | |
| Needham | 09 Apr 2025 | 60.00 (148.86%) | Beli | 24.80 |
| 17 Mar 2025 | 60.00 (148.86%) | Beli | 33.83 | |
| HC Wainwright & Co. | 18 Mar 2025 | 72.00 (198.63%) | Beli | 30.48 |
| 17 Mar 2025 | 72.00 (198.63%) | Beli | 33.83 | |
| Citigroup | 13 Mar 2025 | 70.00 (190.34%) | Beli | 32.13 |
| BMO Capital | 12 Mar 2025 | 72.00 (198.63%) | Beli | 32.61 |
| B of A Securities | 10 Mar 2025 | 48.00 (99.09%) | Beli | 30.04 |
| Scotiabank | 07 Mar 2025 | 70.00 (190.34%) | Beli | 30.29 |
| Barclays | 28 Feb 2025 | 57.00 (136.42%) | Beli | 30.64 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |